ERBB2 and neoplasm: Dacomitinib has demonstrated the inhibition of HER1, HER2, and HER4 in biochemical kinase assays, the dose-dependent inhibition of HER1 and phosphorylation of HER2 RTK in tumor xenografts, and the inhibition of tumor growth or tumor regression in experimental models of cancer [5].